For instance, HSP90 inhibitors improve chemotherapeutic outcomes in several types of cancers when delivered in combination with standard-of-care platinum antitumor compounds (e.g., cisplatin and oxaliplatin) or epidermal growth factor receptor/vascular endothelial growth factor–targeting immunologic agents (cetuximab, panitumumab, and bevacizumab) (30, 57). This evidence concerns the gene EGFR and cancer.